Skip to content
Screener

Boston Scientific BSX Cardiovascular — Selling, general and administrative expenses

Similar metrics at other companies

Lear Corporation logo
LEASeating — Selling, general and administrative expenses
$97.9M+14.5%
Knife River logo
KNFCentral — Selling, general and administrative expenses
$23.27M+26.0%
Ameresco logo
AMRCU.S. Federal — Selling, general and administrative expenses
$4.77M+74.5%
Tejon Ranch logo
TRCMineral resources — Selling, general and administrative expenses
$96K-48.9%
Tilly's logo
TLYSSelling, general and administrative expenses
$45.82M-7.9%
iHeartMedia, Inc. logo
IHRTSelling, general and administrative expenses
$416.72M+18.8%

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$69.19B-54.6%
P/E18.9×-42.3×
P/S3.3×-5.0×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept bsx:SellingGeneralAndAdministrativeExpenseAdjusted.

The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 6:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885725-26-000033
(in millions, except percentages)Med Surg% of Net SalesCardiovascular% of Net SalesTotal
Total net sales$5,203
Segment expenses:
Cost of products sold47828.1%1,06730.5%
Selling, general and administrative expenses55732.8%95927.4%
Research and development expenses1277.5%3439.8%
Other segment items(1)50.3%70.2%
Segment operating income(2)53331.3%1,12532.1%1,658
Unallocated amounts:

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Boston Scientific's cardiovascular — selling, general and administrative expenses?
Boston Scientific (BSX) reported cardiovascular — selling, general and administrative expenses of $959M in Q1 2026.
How has Boston Scientific's cardiovascular — selling, general and administrative expenses changed year-over-year?
Boston Scientific's cardiovascular — selling, general and administrative expenses increased by 9.9% year-over-year, from $873M to $959M.
What is the long-term trend for Boston Scientific's cardiovascular — selling, general and administrative expenses?
Over 3 years (2022 to 2025), Boston Scientific's cardiovascular — selling, general and administrative expenses has grown at a 14.6% compound annual growth rate (CAGR), from $2.45B to $3.69B.
What does cardiovascular — selling, general and administrative expenses mean?
Represents the operating costs incurred to support the Cardiovascular segment, including sales force compensation, marketing, and administrative overhead. These expenses reflect the investment required to maintain and grow the segment's market presence.

Ask your AI about Boston Scientific's cardiovascular — selling, general and administrative expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude